Article

Pathological features and inhaled corticosteroid response of eosinophilic and non-eosinophilic asthma.

Institute for Lung Health, Glenfield Hospital, Leicester LE3 9QP, UK.
Thorax (Impact Factor: 8.56). 01/2008; 62(12):1043-9. DOI: 10.1136/thx.2006.073429
Source: PubMed

ABSTRACT Non-eosinophilic asthma is a potentially important clinicopathological phenotype since there is evidence that it responds poorly to inhaled corticosteroid therapy. However, little is known about the underlying airway immunopathology and there are no data from placebo-controlled studies examining the effect of inhaled corticosteroids.
Airway immunopathology was investigated using induced sputum, bronchial biopsies, bronchial wash and bronchoalveolar lavage in 12 patients with symptomatic eosinophilic asthma, 11 patients with non-eosinophilic asthma and 10 healthy controls. The patients with non-eosinophilic asthma and 6 different patients with eosinophilic asthma entered a randomised, double-blind, placebo-controlled crossover study in which the effects of inhaled mometasone 400 microg once daily for 8 weeks on airway responsiveness and asthma quality of life were investigated.
Patients with non-eosinophilic asthma had absence of eosinophils in the mucosa (median 4.4 cells/mm(2) vs 23 cells/mm(2) in eosinophilic asthma and 0 cells/mm(2) in normal controls; p = 0.03) and normal subepithelial layer thickness (5.8 microm vs 10.3 microm in eosinophilic asthma and 5.1 microm in controls, p = 0.002). Non-eosinophilic and eosinophilic asthma groups had increased mast cell numbers in the airway smooth muscle compared with normal controls (9 vs 8 vs 0 cells/mm(2), p = 0.016). Compared with placebo, 8 weeks of treatment with inhaled mometasone led to less improvement in methacholine PC(20) (0.5 vs 5.5 doubling concentrations, 95% CI of difference 1.1 to 9.1; p = 0.018) and asthma quality of life (0.2 vs 1.0 points, 95% CI of difference 0.27 to 1.43; p = 0.008).
Non-eosinophilic asthma represents a pathologically distinct disease phenotype which is characterised by the absence of airway eosinophilia, normal subepithelial layer thickness and a poor short-term response to treatment with inhaled corticosteroids.

Download full-text

Full-text

Available from: Dominick Shaw, Jan 29, 2014
0 Followers
 · 
110 Views
  • Source
    • "Most often primary cares' physicians do not require a chest X-ray (CXR) mainly because of the tremendous cost expenses and lack of X-ray equipment setups as well as lack of specialist staff. On the other hand the dynamic of blood cell count (CBC) has been used as a reliable clinical predictor for the severity of a variety of inflammatory conditions [35] [4], yet its implementations to classify asthma severity have been ignored. Clearly, chronic inflammatory process of the airways must be associated with a significant rise in white cell count (WBC), yet its implementations to classify the severity of asthma had been poorly understood. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The purpose of the present study was to rate the level of spread of asthma-induced bronchial morphological changes on chest X-ray (CXR), using the modified Shwachman–Kulczycki (S–K) rating scale as predicted by the dynamic of blood cell count (CBC). A sample of 40 asthma patients’ records was classified into 4 groups based on their clinical presentations and frequency of their visits to the hospital; Group-1 ⩽2 visits per week with reversible symptoms, Group-2 ⩾2 visits per week with irreversible symptoms, Group-3: ⩾3–4 visits per week with irreversible symptoms; Group-4: patients with severe shortness of breath in whom SaO2 was threatening, hence were admitted as inpatients. Patients’ CXR were scored based on the modified Shwachman–Kulczycki (S–K) scale rating. Blood analysis showed that RBC and their indices (HCT, HGB, MCH, RDW) were highest in group-2. White blood cells and their derivatives (NEU, EOS and LYM) were highest in group 4. CXR for group-2 showed bilateral increased bronchovascular markings but normal both lung fields and ruled out for costo-phrenic angles type of fever. Chest X-ray for group-3 showed hyperinflation, perihilar marking associated with bronchial thickening and unfolding aorta. In patients in group-4 development of broncho-pneumonic infiltration type of SOB and some evidence of bronchial edema with significant (p < 0.05) elevation in WBC were observed. The regression of S–K score on the dynamic of some CBC parameters was significant (p < 0.05). The best subsets that describe the model were:
    02/2015; 354(2). DOI:10.1016/j.ejcdt.2014.11.012
  • Source
    • "La mesure de l'inflammation éosinophilique des voies aériennes de l'asthmatique a donc un intérêt clinique majeur car elle permet de prédire une réponse favorable aux corticostéroïdes inhalés (CSI) et peut ainsi aider à guider le traitement [57] . Une étude récente de cross-over, placebo-contrôlée a également confirmé qu'une réponse favorable au traitement par mométasone 400 ␮g durant 8 semaines était réservée aux patients qui présentaient une éosinophilie bronchique [58] . Ces résultats suggèrent que la mesure de l'inflammation bronchique est un meilleur guide pour l'évaluation de la nécessité d'introduire un traitement par corticostéroïdes que la recherche d'anomalies de la fonction respiratoire. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Intérêt de la mesure de l'inflammation en clinique dans l'asthme F. Schleich, R. Louis L'évaluation de la composante inflammatoire chez le patient asthmatique par l'analyse de l'expectoration induite, la mesure du monoxyde d'azote dans l'air exhalé (FE NO) ou des condensats d'air exhalé est une étape importante de la caractérisation phénotypique de la maladie. La mesure de l'inflammation éosinophilique des voies aériennes de l'asthmatique a un intérêt clinique majeur car elle permet de prédire une réponse favorable aux corticostéroïdes inhalés et peut ainsi guider le traitement. Dans cette synthèse, nous présenterons les différentes techniques d'objectivation d'une inflammation corticosensible, leurs méthodologies, l'interprétation à donner à leurs résultats et leurs intérêts en pratique clinique.
    Edited by Encyclopédie Médico-chirurgicale EMC Pneumologie, 07/2012;
  • [Show abstract] [Hide abstract]
    ABSTRACT: Asthma is an increasingly prevalent disease, particularly in industrialized countries. With modern treatment, many patients can expect good asthma control; however, a significant minority continue to have excessive symptoms. Bronchial thermoplasty is a novel approach to treating asthma in which the hypertrophied airway smooth muscle present in the asthmatic airway is specifically targeted and depleted using thermal energy. In this article, we review the early animal and human development of the technique, summarize the randomized trials carried out in patients to date, discuss proposed mechanisms of action, and suggest directions for future work.
    Current Allergy and Asthma Reports 01/2008; 9(1):88-95. DOI:10.1007/s11882-009-0013-6
Show more